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Objectives: To characterize NAI-107 and related lantibiotics for their in vitro activity against Gram-negative patho-
gens, alone or in combination with polymyxin, and against non-dividing cells or biofilms of Staphylococcus aureus.
NAI-107 was also evaluated for its propensity to select or induce self-resistance in Gram-positive bacteria.
Methods: We used MIC determinations and chequerboard experiments to establish the antibacterial activity of
the examined compounds against target microorganisms. Time–kill assays were used to evaluate killing of expo-
nential and stationary-phase cells. The effects on biofilms (growth inhibition and biofilm eradication) were eval-
uated using biofilm-coated pegs. The frequency of spontaneous resistant mutants was evaluated by either direct
plating or by continuous sub-culturing at 0.5%MIC levels, followed by population analysis profiles.
Results: The results showed that NAI-107 and its brominated variant are highly active against Neisseria gonor-
rhoeae and some other fastidious Gram-negative pathogens. Furthermore, all compounds strongly synergized
with polymyxin against Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aer-
uginosa, and showed bactericidal activity. Surprisingly, NAI-107 alone was bactericidal against non-dividing
A. baumannii cells. Against S. aureus, NAI-107 and related lantibiotics showed strong bactericidal activity against
dividing and non-dividing cells. Activity was also observed against S. aureus biofilms. As expected for a lipid II
binder, no significant resistance to NAI-107 was observed by direct plating or serial passages.
Conclusions: Overall, the results of the current work, along with previously published results on the efficacy of
NAI-107 in experimental models of infection, indicate that this lantibiotic represents a promising option in ad-
dressing the serious threat of antibiotic resistance.
Introduction
The increasing incidence of MDR pathogens has led to the dire pre-
diction that humanity will soon enter the post-antibiotic era, when
today’s routine surgical procedures will become high-risk endeav-
ours.1,2 This worrisome scenario is exacerbated by the paucity of
new antibiotics reaching the market, and in particular of new
chemical classes suitable for systemic administration and not af-
fected by prevailing resistance mechanisms. Indeed, since the be-
ginning of the century most antibacterial drugs introduced into
human use or under advanced clinical development represent im-
proved analogues of marketed compounds.3
Of particular concern are infections caused by the ESKAPE
pathogens, which include Enterococcus faecium, Staphylococcus
aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudo-
monas aeruginosa and Enterobacter spp.4 In particular, infections
by MRSA are associated with community and hospital infections,
and up to 80% of all MRSA infections in the USA have been ascribed
to the MRSA clone USA300, which is also highly resistant to other
antibiotics.5 Given the limited options available to treat ESKAPE
pathogens, it is important to develop new antibiotics that are not
affected by prevailing resistance mechanisms, while at the same
time devising strategies that minimize the spread of antibiotic
resistance.
VC The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the
original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
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One class of antibiotics that has been receiving increasing at-
tention is represented by the lantibiotics. These compounds, which
belong to the growing family of ribosomally synthesized and post-
translationally modified peptides, are characterized by the
presence of (methyl)-lanthionine bridges that confer rigidity and
stability on the peptide.6 The prototype lantibiotic is nisin, which
has been used for decades as a food preservative.
One of the most potent lantibiotics is NAI-107 (Figure 1), a
chlorine-containing compound active against MDR Gram-positive
pathogens, including MRSA, glycopeptide-intermediate S. aureus
(GISA), VRE and penicillin-resistant Streptococcus pneumoniae.7,8
Lantibiotics with similar antibacterial properties have been ob-
tained after incorporation of Br into NAI-107, leading to NAI-108,9
or after semi-synthetic conversion, leading to NAI-857DA and
related compounds.10 NAI-857DA and NAI-107/108 share a simi-
lar peptide scaffold and identical topology of thioether rings, with
the first two N-terminal rings shared with nisin (Figure 1). A rapid
bactericidal activity9–11 and a prolonged half-life in plasma12 are
consistent with the efficacy of NAI-107 in different experimental
models of infection in rodents13 and insects.14 The ratio between
the area under the concentration–time curve and the MIC has
been proposed as the pharmacodynamic index predictive of effi-
cacy in the mouse.12
The scope of this study was to characterize the in vitro proper-
ties of NAI-107 with respect to the propensity to select for resist-
ance, its activity against biofilms and non-dividing cells of
S. aureus, and its activity against Gram-negative pathogens, alone
or in combination with polymyxin B. Where appropriate, the prop-
erties of NAI-108 and NAI-857DA were also investigated.
Materials and methods
Materials and methods are available as Supplementary data at JAC Online.
Results
Activity against fastidious Gram-negative pathogens
Most antibiotics targeting lipid II are large molecules that cannot
cross the outer membrane barrier present in Gram-negative bac-
teria.15 However, in contrast to most clinically used drugs targeting
Gram-positive pathogens, NAI-107 extends its antibacterial spec-
trum to some fastidious Gram-negative bacteria (Table 1), includ-
ing Neisseria meningitidis (MIC range 0.06–1 mg/L), Moraxella
catarrhalis (MIC range 0.25–1 mg/L) and Haemophilus influenzae
(MIC range 8–16 mg/L). Although only a few strains were tested in
comparison, NAI-107 was considerably more active than nisin
(Table 1), suggesting that the activity against these bacterial spe-
cies is not a general property of lantibiotics. No activity was seen
against individual strains of Salmonella Enteritidis, Enterobacter
cloacae and Proteus mirabilis (data not shown).
Interestingly, NAI-107 was highly active against Neisseria gon-
orrhoeae, including isolates with intermediate or high resistance to
penicillin. Against 18 tested strains, the observed MICs ranged
from 0.015 to 2 mg/L (Table 2), with no apparent correlation to a
strain’s susceptibility to penicillin. Similar results were observed
with NAI-108, which, as previously observed with Gram-positive
pathogens,9 was usually twice as active as NAI-107 (Table 2).
In contrast, NAI-857DA was substantially less active than the
other two lantibiotics (Table 2).
NAI-107 was essentially inactive against three strains each of
the Gram-negative pathogens Escherichia coli, K. pneumoniae and
P. aeruginosa, with no measurable MICs at the highest concentra-
tion tested (Table 3). Some activity could, however, be observed
against A. baumannii, with one strain showing an MIC of 32 mg/L
(Table 4). In about half of 12 independent A. baumannii isolates,
NAI-108 was slightly more active than NAI-107, with 16 mg/L as
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Figure 1. Structures of NAI-107 (top, where X"Cl), NAI-108 (top, where X"Br) and NAI-857DA (bottom). Note that NAI-107 and NAI-108 are ob-
tained directly from fermentation, whereas NAI-857DA is obtained by converting the natural lantibiotic NAI-857 into its diamide.8,10
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the lowest observed MIC (Table 4). It should be noted that none of
the analysed strains was resistant to polymyxin (Table 4; see also
below).
The acquisition of polymyxin resistance in Gram-negative spe-
cies involves LPS modifications16–18 and vancomycin is active
against some LPS-deficient A. baumannii mutants.19 We thus
tested the LPS-deficient A. baumannii mutants AB167R and
AB176R (defective in LPS formation) and CR17 (which adds phos-
phoethanolamine to LPS), as well as the polymyxin-susceptible
WT ATCC 19606.20 The LPS-deficient strains proved susceptible
to NAI-107 (Table 4), with MICs of 2–4 mg/L, while the WT and
the pmrA mutant were not susceptible (MIC .128 mg/L).
Therefore, the activity of NAI-107 against Gram-negative spe-
cies should be achievable via permeabilization of the outer
membranes.
Synergism with polymyxin
Antibiotics (e.g. vancomycin, daptomycin) that are not effective
against Gram-negative bacteria can become active if the perme-
ability barrier provided by the outer membrane is weakened by
sub-inhibitory concentrations of polymyxin or colistin.21–24 These
drugs have become the last options to treat infections by MDR
Gram-negative pathogens, but they also have significant toxicity.
If polymyxin or colistin concentrations could be substantially
reduced in effective combinations with NAI-107, the toxic effect
would be less severe.
We thus tested combinations of NAI-107 and polymyxin
against three independent isolates each of the target pathogens
A. baumannii, E. coli, K. pneumoniae and P. aeruginosa. Against
A. baumannii, the fractional inhibitory concentrations (FICs) of
polymyxin and NAI-107 were 0.03–0.125 and 0.016–0.06, respect-
ively, with FIC indexes ranging from 0.09 to 0.14 (Table 3).
Similarly, polymyxin and NAI-107 formed synergistic combinations
against all the tested strains of the other examined species:
the lowest FICs of polymyxin against E. coli, K. pneumoniae and
P. aeruginosa were 0.03–0.06, 0.06–0.25 and 0.125–0.25, respect-
ively, with growth inhibition requiring NAI-107 concentrations of
2–8, 2–16 and 4–32 mg/L, respectively (Table 3). Since NAI-107
was inactive against these strains, FIC indexes were essentially
determined by the polymyxin FIC and ranged from 0.28 (for
K. pneumoniae L3392) to 0.04 (for E. coli L47).
We also evaluated the lowest polymyxin concentration
required to inhibit the growth of the analysed strains in the pres-
ence of 2 mg/L NAI-107, a concentration that can be readily main-
tained after systemic administration in rodents.12,13 With the
exception of P. aeruginosa ATCC 27853, for which the polymyxin
concentration was 0.125 mg/L (i.e. 0.5%MIC), in all other cases
0.06 mg/L polymyxin was sufficient to inhibit growth in the pres-
ence of 2 mg/L NAI-107 (Table 3).
Polymyxin is known to rapidly kill susceptible Gram-negative
bacteria,25 as does NAI-107 for Gram-positives.11 We thus tested
different growth-inhibiting combinations of polymyxin and NAI-
107 for their ability to reduce the viable bacterial counts in dynamic
chequerboards. We did observe a decrease in viable counts in com-
binations containing NAI-107 and sub-inhibitory concentrations
of polymyxin but not in cultures treated with polymyxin alone.
At 0.031 mg/L polymyxin (i.e. 0.25%MIC), the viable count for
A. baumannii L3030 was undistinguishable from that of the un-
treated control (Figure 2a). However, addition of as little as
Table 1. MIC (mg/L) or MIC ranges (mg/L) of NAI-107 for selected Gram-negative pathogens
Species Number of tested strains NAI-107 Vancomycin Teicoplanin Linezolid Nisin
H. influenzaea 18 8–16 64 to.128 64–128 8–32 .128d
M. catarrhalisb 8 0.25–1 32–64 4–32 4–8 1–4d
N. meningitidisc 4 0.06–1 32 to.128 16–128 8–32 8e
aTested strains include ATCC strains 49247, 9334, 19418 and 9006, and 14 clinical isolates collected in Italy and the UK.
bTested strains include ATCC 8176 and seven clinical isolates collected in the USA and the UK.
cTested strains include ATCC 13804, 13090, 13102 and 13113.
dOnly two strains tested with this antibiotic.
eOnly one strain tested with this antibiotic.
Table 2. MICs (mg/L) of NAI-107, NAI-108, NAI-857DA and penicillin for
N. gonorrhoeae
Strain codea NAI-107 NAI-108 NAI-857DA Penicillin
ATCC 49226 0.25 0.125 2 1
L1596 0.125 0.125 4 0.015
L1599 0.015 0.015 0.25 0.25
L1601 0.5 0.25 8 .32
L1602 0.25 0.125 8 .32
L1603 1 1 16 .32
L1604 0.5 0.25 4 .32
L1605 0.25 0.125 8 .32
ND755 1 1 8 2
ND756 0.25 0.125 2 0.5
ND757 1 0.5 16 4
ND758 1 0.5 8 4
ND759 0.25 0.125 2 0.25
ND760 1 0.5 8 4
ND761 1 0.5 16 4
ND762 0.5 0.25 16 2
ND763 1 0.5 8 2
ND764 2 1 8 2
aStrains with an L or ND prefix are clinical isolates collected in Italy or
the USA.
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0.5 mg/L NAI-107 was sufficient to decrease viable counts by at
least four orders of magnitude (i.e. below the detection limit
of 50 cfu/mL) for up to 20 h (Figure 2a and Table S1). Similarly,
in the presence of 0.016 mg/L polymyxin, NAI-107 caused a
concentration-dependent decrease in viable counts, with 2 mg/L
NAI-107 being sufficient to decrease the viable counts below the
detection limit, whereas 1 mg/L NAI-107, despite an initial de-
crease in viable counts, was unable to prevent full growth at 20 h
(Figure 2a). In bactericidal combinations viable counts decreased
in a time-dependent manner, with 1 h of incubation sufficient to
decrease cfu/mL by 2.5–3.5 log, whereas a 3 h incubation was
required to reduce cfu/mL below the detection limit (Figure 2a).
Next, we used A. baumannii L3030 to test the effects of the lan-
tibiotics NAI-108 and NAI-857DA, and of vancomycin. As seen for
NAI-107, NAI-108 showed time- and concentration-dependent
killing, with 2 and 0.5 mg/L NAI-108 being sufficient to decrease
viable counts below the detection limit in the presence of 0.016
and 0.031 mg/L polymyxin, respectively (Figure 2b). In contrast, at
least 2 mg/L NAI-857DA (Figure 2c) or 2 mg/L vancomycin (Figure
2d) was necessary for reducing viable counts of A. baumannii
L3030 below the detection limit in the presence of 0.031 mg/L
polymyxin. Lowering the concentration of polymyxin to 0.016 mg/L
required 4 and 64 mg/L NAI-857DA (Figure 2c) and of vancomycin
(Table 5), respectively, for observing a complete bactericidal effect
for the entire duration of the experiment. Only when polymyxin
concentrations were raised to 0.062 mg/L (i.e. 0.5%MIC) did we
Table 3. In vitro synergism with polymyxin B
Species Strain code
Polymyxin NAI-107
FIC index
Polymyxin (mg/L)
at 2 mg/L NAI-107a
MIC
(mg/L) FIC
MIC
(mg/L)
concentration of
NAI-107 in the most
synergistic combination (mg/L) FIC
A. baumannii L373b 0.5 0.03 128 8 0.06 0.09 0.03
L3030c 0.125 0.06 128 4 0.03 0.09 0.016
L2859b 0.25 0.125 32 0.5 0.016 0.14 0.06
E. coli L47d 0.125 0.03 .256 4 0.008 0.04 0.008
ATCC 25922 0.125 0.03 .256 8 0.016 0.05 0.004
ND480b 0.25 0.06 .256 2 0.004 0.07 0.016
K. pneumoniae L3392b 0.06 0.25 .256 16 0.03 0.28 0.03
ND484e 0.25 0.06 .64 4 0.03 0.09 0.03
ND443b 0.25 0.06 .256 2 0.004 0.07 0.016
P. aeruginosa ATCC 10145 0.125 0.125 .256 4 0.008 0.13 0.03
ATCC 25668 0.125 0.125 .256 32 0.06 0.19 0.06
ATCC 27853 0.25 0.25 .256 8 0.016 0.27 0.125
The table reports the concentrations of polymyxin (as fractions of the MIC) and those of NAI-107 giving the lowest calculated FIC index for each
strain.
aLowest polymyxin concentration required for growth inhibition in the presence of 2 mg/L NAI-107.
bClinical isolate collected in Italy.
cClinical isolate collected in the UK.
dStrain from historical Lepetit collection.
eClinical isolate collected in the USA.
Table 4. Antibacterial activities against A. baumannii
Strain codea
MIC (mg/L)
NAI-107 NAI-108 polymyxin colistin
L256 128 128 1 1
L2831 128 32 0.06 1
L2859 32 16 0.06 0.125
L2860 128 128 0.125 0.5
L364 .128 .128 0.06 0.5
L373 128 64 0.25 1
L3030 128 128 0.25 0.25
ATCC 17904 128 128 0.06 0.06
L756 128 128 0.06 0.06
ND021808 128 128 0.06 0.06
ND045309 64 32 0.06 0.06
ND048710 128 64 0.06 0.25
ND049010 128 128 0.125 0.25
WT 19606 .128 NT NT 0.5
AB167 (lpxC)b 2–4 NT NT .128
AB176 (lpxD)b 2–4 NT NT .128
CR17 (pmrA)b .128 NT NT 64
NT, not tested.
aStrains with an L or ND prefix are clinical isolates collected in Italy.
bStrains described by Garcı´a-Quintanilla et al.19
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observe a bactericidal effect at vancomycin concentrations of
0.5 mg/L (Figure 2d). It should be noted that 0.062 mg/L poly-
myxin alone did have a transient effect on cell viability, with a small
decrease in viable cells up to 3 h, followed by full growth by 20 h
(Figure 2d). Overall, these results are consistent with the general
trend observed with the lantibiotics shown in Figure 1, with the
hydrophobic lantibiotics NAI-107 and NAI-108 showing compar-
able activities, whereas the hydrophilic NAI-857DA was slightly less
active than the other two compounds.8 Vancomycin was less po-
tent than NAI-107 in synergistic combinations with polymyxin.
Table 5 describes a summary of the results observed with growth
and viable counts in chequerboard experiments. Usually, in the
presence of a given polymyxin FIC, the lowest concentration of
antibiotic able to reduce viable counts below the detection limit at
3 h coincided with the concentration that was able to prevent
growth (Table 5).
We next expanded the evaluation of NAI-107 using selected
strains from Table 3. As seen with A. baumannii L3030,
within 1–3 h NAI-107 was able to significantly reduce viable
counts (below or close to the detection limit) of A. baumannii
L373 (Figure 2e), E. coli ATCC 25922 (Figure 2f), E. coli L47 (data
not shown), K. pneumoniae ND484 (Figure 2g) and P. aeruginosa
ATCC 10145 (Figure 2h), most of the time at the same concen-
trations as those sufficient to cause growth inhibition (Table S2).
With P. aeruginosa ATCC 10145, 0.5%MIC polymyxin caused
a transient decrease in viable counts, followed by regrowth.
The addition of 0.125 mg/L NAI-107 prevented regrowth
(Figure 2h).
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Figure 2. Killing of A. baumannii L3030 by NAI-107 (a), NAI-108 (b), NAI-857DA (c) or vancomycin (d), each in combination with polymyxin, and kill-
ing by NAI-107 in combination with polymyxin of A. baumannii L373 (e), E. coli ATCC 25922 (f), K. pneumoniae ND484 (g) or P. aeruginosa ATCC 10145
(h). Untreated controls are represented by broken lines. Polymyxin concentrations are represented as follows: 0.016 mg/L, squares and black lines;
0.031 mg/L, circles and red lines; and 0.062 mg/L, triangles and blue lines. Cultures containing polymyxin only are represented by open symbols, while
filled symbols indicate the presence of a combination antibiotic (NAI-107, NAI-108, NAI-857DA or vancomycin) at the following concentrations:
0.125 mg/L, light green; 0.25 mg/L, purple; 0.5 mg/L, black; 1 mg/L, blue; 2 mg/L, red; 4 mg/L, green; and 8 mg/L, orange. The limit of detection was
50 cfu/mL.
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Activity against S. aureus biofilms
NAI-107 and related lantibiotics are active against most Gram-
positive pathogens, including MRSA and GISA.7,9,10 In order to
evaluate activity against biofilms, four S. aureus strains were se-
lected for their ability to form biofilms (Table S1). Against these
strains, NAI-107, NAI-108 and NAI-857DA were able to inhibit
growth of planktonic cells detaching from the biofilms, with min-
imal biofilm-inhibiting concentrations (MBICs) comparable to MICs
(Table 6). The minimal biofilm-eradicating concentration (MBEC)
values were usually 16–32 mg/L, with the exception of NAI-857DA,
which showed an MBEC of 2 mg/L against a single strain.
Rifampicin and amoxicillin, used as positive and negative controls,
respectively, behaved as expected (Table 6).
Table 5. Effect of polymyxin-containing combinations on growth and viability of A. baumannii L3030
Polymyxin
(mg/L)
NAI-107 (mg/L) NAI-108 (mg/L) NAI-857DA (mg/L) Vancomycin (mg/L)
growth
inhibition
killing ata
growth
inhibition
killing ata
growth
inhibition
killing ata
growth
inhibition
killing ata
1 h 3 h 20 h 1 h 3 h 20 h 1 h 3 h 20 h 1 h 3 h 20 h
0.062 0.5 NT NT NT 0.25 NT NT NT 0.13 NT NT 0.13 0.5 0.5 0.5 0.5
0.031 0.5 4 0.5 0.5 0.25 8 2 0.5 0.5 .2 1 2 2 4 4 4
0.016 2 8 2 2 0.5 8 2 2 4 .8 4 4 64 NT NT NT
0.008 8 16 4 8 4 16 4 8 8 .8 8 .8 128 NT NT NT
0.004 4 16 4 4 16 32 16 32 32 NT NT NT 128 NT NT NT
0.002 8 16 16 16 32 NT NT NT 64 NT NT NT 128 NT NT NT
NT, not tested.
At the indicated polymyxin concentration, the table reports for each compound the lowest concentration able to inhibit growth and the lowest con-
centration necessary to reduce the number of viable cells below the detection limit (50 cfu/mL) in replicated microtitre plate experiments.
aLowest concentration required to reduce the number of viable counts below the detection limit after 1, 3 or 20 h. Note that the symbol  is used
only when cfu/mL was not determined from cultures that were fully inhibited at concentrations lower than indicated. cfu/mL at time zero ranged
from 3%105 (vancomycin experiment) to 1%106 (NAI-857DA experiment).
Table 6. Activities against S. aureus biofilms (values in mg/L)
Microorganism Parameter NAI-107 NAI-108 NAI-857DA Rifampicin Amoxicillin
S. aureus L3988 MIC 1 NT 1 0.002 16
MBIC 2 NT 2 0.007 .128
MBEC 16 NT 2 0.03 .128
S. aureus L3797 MIC 4 8 8 0.002 128
MBIC 8 16 32 0.002 .128
MBEC 16 16 32 0.03 .128
S. aureus USA300 MIC 0.5 1 1 0.002 64
MBIC 0.125 0.5 1 0.002 .128
MBEC 16 32 32 0.03 .128
S. aureus L1400 MIC 1 2 2 0.002 128
MBIC 1 2 2 0.002 128
MBEC 32 16 16 0.06 .128
See the Materials and methods section for details.
Table 7. MICs for the S. aureus strains used in time–kill experiments
MIC (mg/L)
vancomycin NAI-107 NAI-108 NAI-857DA
USA300 2 0.25 1–2* 1
Mu3 4*–8 4 8*–16 4*–8
Mu50 1 2 8 4
MICs were determined for three individual clones. When more than
one value was found, the MIC values used for further study are those
found in two of three determinations and are designated by an
asterisk.
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NAI-107 effectively kills non-dividing S. aureus cells
Daptomycin and oritavancin were shown to kill S. aureus cells in
stationary phase, whereas vancomycin was inactive.26,27
Therefore, we compared the effect of our lantibiotics on exponen-
tially growing and non-dividing cells of S. aureus, using vancomycin
as control. After determining the MICs of the compounds (Table 7),
time–kill experiments were initially performed on the community-
acquired MRSA strain USA300 and the glycopeptide-intermediate
S. aureus (GISA) strain Mu50.28
Vancomycin demonstrated killing of exponentially growing
USA300 by.99.9% within 3 h at 1%MIC (2 mg/L), with no increase
in viable counts seen up to 24 h (Figure 3a). Treatment of USA300
with the three lantibiotics resulted in reduction in bacterial titres of
at least 99% within 1 h at all concentrations tested. However, vi-
able counts at 24 h were comparable to untreated controls at
1%MIC NAI-107 (0.25 mg/L), but not at higher concentrations
(Figure 3c), and in the presence of all concentrations of NAI-857DA
(1–5 mg/L; Figure 3g). This phenomenon was not observed with
NAI-108 at all concentrations tested (2–10 mg/L; Figure 3e).
Against Mu50, vancomycin showed an effect pronouncedly dif-
ferent from that seen against USA300 (Figure 3b). At 1%MIC
(4 mg/L), there was no change in the number of viable cells for the
first 5 h, and by 24 h the strain had reached the same density as
the untreated control. Increasing vancomycin concentration to
3% or 5%MIC resulted in slow killing up to 5 h, but viable counts
could still be observed at 24 h (Figure 3b). In contrast, the response
of USA300 and Mu50 to the lantibiotics was similar: at 3% or
5%MIC, NAI-107, NAI-108 and NAI-857DA reduced viable counts
of Mu50 (Figure 3d, f and h).
We next examined the activity of NAI-107, NAI-108 and NAI-
857DA against non-dividing cells resuspended in PBS at
5%105 cfu/mL. In these experiments, we also included the GISA
strain Mu3.28 NAI-107, NAI-108 and NAI-857DA were tested at
3%, 5% and 10%MIC, whereas vancomycin, which was expected
to have little activity, was used as a control at 10%MIC only.
Against USA300, NAI-107 showed time- and concentration-
dependent killing of non-dividing cells, with cfu/mL decreased by
99% within 5 h at 5%MIC and within 1 h at 10%MIC (Figure 4a).
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Figure 3. Killing of exponentially growing S. aureus USA300 (a, c, e and g) and Mu50 (b, d, f and h) by vancomycin (VAN; a and b), NAI-107 (c and d),
NAI-108 (e and f) or NAI-857DA (g and h), as indicated. Compounds were added at 1%MIC (green lines and circles), 3%MIC (blue lines and squares)
or 5%MIC (red lines and diamonds). Broken lines denote untreated controls. Data represent the average of three independent treatments. Standard
deviations are omitted for clarity. The limit of detection was 33 cfu/mL. Note that one of three USA300 cultures treated with 5%MIC NAI-857DA
showed no growth and these data were not considered in calculating the average cfu/mL in (h).
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Against Mu50 (Figure 4b) and Mu3 (Figure 4c), NAI-107 treatment
resulted in99% reduction of viable cells within 1–5 h, with the ef-
fect lasting the remainder of the experiment. Similar results were
observed when USA300 was resuspended in spent medium rather
than in PBS (data not shown).
When exposed to NAI-108, viable cells of USA300 (Figure 4d)
and Mu50 (Figure 4e) dropped below the detection limit within 1 h
at all concentrations tested. Only with Mu3 did we observe
concentration-dependent killing, with 10%MIC NAI-108 required
to reduce viable counts below 0.1% of the starting titre (Figure 4f).
When exposed to NAI-857DA, USA300 cells were killed within 3 h
at all tested concentrations (Figure 4g), Mu50 cells were resistant
to killing (Figure 4h) and strain Mu3 appeared to have an inter-
mediate behaviour, with time-dependent and concentration-
independent killing (Figure 4i).
Altogether, the above results indicate that dividing and non-
dividing cells of the MRSA strain USA300 are rapidly killed by NAI-
107 and by NAI-108 at equivalent multiples of the MIC, whereas
this strain is able to eventually escape killing by NAI-857DA in
growth medium but not in PBS. Under non-dividing conditions, the
GISA strains Mu3 and Mu50 are rapidly killed by NAI-107 and by
NAI-108, but only partially and slowly by NAI-857DA.
NAI-107 effectively kills non-dividing A. baumannii cells
Inspired by the above results, we exposed non-dividing cells of
A. baumannii L3030 in PBS to combinations of NAI-107 and poly-
myxin. Under these conditions, the untreated strain was stable
(just a few duplications observed during the incubation period) and
killed by 0.5 mg/L polymyxin (Figure 5). Notwithstanding an
MIC of 128 mg/L, NAI-107 alone was able to kill the strain within 3 h
at16 mg/L, with no detectable cells observed after 20 h. A similar
killing effect by 16 mg/L NAI-107 was observed against non-
dividing cells of A. baumannii L2859 (data not shown). It should be
noted that the activities against dividing and non-dividing cells
were measured under similar conditions, with the main difference
represented by the presence of growth medium versus PBS.
Furthermore, NAI-107 in PBS led to a decrease in cfu/mL after 3 h
(Figure 5), at the same time that an increase in viable counts was
observed in growth medium (Figure 2a). None of the other Gram-
negatives tested (E. coli ATCC 25922, K. pneumoniae L3392 and
P. aeruginosa ATCC 27853) was killed by NAI-107 under non-
dividing conditions (data not shown).
Consistent with the data observed with growing cells, combin-
ations of NAI-107 and polymyxin were highly effective in killing
non-dividing A. baumannii L3030: at polymyxin concentrations of
0.125 or 0.06 mg/L,2 mg/L NAI-107 was sufficient to reduce the
number of viable counts below the detection limit (Figure 5). When
4 mg/L NAI-107 was used, killing was observed at 0.016 mg/L poly-
myxin, the lowest concentration tested (Figure 5).
Lack of in vitro resistance in Gram-positives
In contrast to molecules targeting cellular proteins, antibiotics
binding to lipid II do not select resistant mutants by direct
plating.15,29 Consistently, no spontaneous resistance mutants of
two GISA strains, two MRSA strains and one E. faecalis VanA strain
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Figure 4. Killing of non-dividing cells of S. aureus strain USA300 (a, d and g), Mu50 (b, e and h) and Mu5 (c, f and i) by NAI-107 (a–c), NAI-108 (d–f) or
NAI-857DA (g–i), as indicated. Antibiotics were added at 3%MIC (green lines and circles), 5%MIC (blue lines and squares) or 10%MIC (red lines and
diamonds). Broken lines denote untreated controls. Vancomycin was added at 10%MIC and is shown only for (a), (b) and (c) (black lines and open tri-
angles). Overnight cultures were diluted to5%105 in pre-heated PBS (37 C). Experiments were performed in triplicate. Standard deviations are omit-
ted for clarity. The limit of detection was 33 cfu/mL. Note that one of three Mu50 cultures treated with NAI-857DA showed growth equivalent to
controls and these data were not considered in calculating the average cfu/mL in (h).
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were observed at 10%MIC NAI-107, indicating a frequency lower
than 10#10 (Table S3).
Using 12 strains (1 MSSA, 2 MRSA, 3 GISA, 3 E. faecalis VanA and
3 E. faecium VanA), 20 serial subcultures in the presence of subinhi-
bitory concentrations yielded only modest increases in the NAI-
107 MIC, which appeared to stabilize at 2- or 4-fold the initial value,
with isolated spikes at 8-fold (Figure 6). Population profile analyses
of cultures emerging after 1 passage, 10 passages or 20 passages
indicated that the procedure had probably enriched for a subpopu-
lation of cells already present in the initial culture, with no signifi-
cant differences seen after 10 or 20 passages (Figure 7).
Discussion
Gram-negative bacteria can be sensitized to different antibiotics
by sub-inhibitory concentrations of polymyxin or colistin.30 We
could find only a few reports addressing the ability of polymyxin-
based combinations to kill the target pathogens: these studies
were performed at 1 mg/L polymyxin and at a single, high concen-
tration (20 mg/L) of vancomycin,21 teicoplanin31 or telavancin.22
In this study, we show that, in addition its strong synergism, essen-
tially the same combinations of NAI-107 and polymyxin that in-
hibit growth also reduce viable counts below the detection limit of
the Gram-negative pathogens.
Few studies have investigated antibacterial activity against
non-dividing S. aureus cells. Mascio et al.27 demonstrated that dap-
tomycin kills MRSA in stationary phase, with a mechanism that
does not require energy or protein synthesis. In their elegant stud-
ies, Mu¨ller et al.32 demonstrated that daptomycin binds to high-
fluidity regions in the membrane, thus preventing the function of
proteins that specifically localize to those regions. Combining the
two observations, we surmise that high-fluidity regions are present
in non-dividing cells. Unlike vancomycin, oritavancin kills non-
dividing S. aureus cells, and septum staining of stationary phase
cells is affected by oritavancin and not by vancomycin.26
NAI-107 forms 1:1 or 2:1 complexes with bactoprenol–
pyrophosphate-coupled precursors of the bacterial cell wall, such
as lipid II. In whole cells, NAI-107 does not form nisin-like pores in
the bacterial membrane, but binding of NAI-107 to lipid II is fol-
lowed by a slow membrane depolarization.11 Current evidence in-
dicates that NAI-107, like nisin, binds to the pyrophosphate moiety
of lipid II,11 a site distinct from the binding site of glycopeptides.
Indeed, vancomycin does not kill non-dividing S. aureus,26 as
confirmed here, consistent with the fact that the D-Ala-D-Ala
moiety (i.e. vancomycin’s target) is not present in mature
peptidoglycan.33
Altogether, the observed killing by NAI-107 of MRSA and GISA
cells under non-dividing conditions is consistent with the
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hypothesis that killing requires interaction with the membrane. In
the case of NAI-107, we believe this interaction occurs after an ini-
tial docking on lipid II or other bactoprenol–pyrophosphate-based
intermediates. Indeed, it has been recently reported that peptido-
glycan recycling is important for survival in the stationary phase of
Gram-positive bacteria, including S. aureus.34 Although not dem-
onstrated by these authors, such recycling might involve
pyrophosphate-based carriers similar to lipid II, and would explain
NAI-107’s activity against non-dividing cells. A similar explanation
might apply also to the reported killing of non-dividing cells by
oritavancin.26
We were surprised to observe that NAI-107 can also kill non-
dividing cells of two A. baumannii strains at sub-MIC values. This
phenomenon might be a general feature of this species, as it was
not observed with E. coli, K. pneumoniae and P. aeruginosa. Thus, it
is tempting to speculate that the permeability of the A. baumannii
outer membrane might change as the cells go from a non-dividing
to a dividing state, allowing NAI-107 to reach its target under the
former conditions. Among the four pathogenic species in Table 3,
A. baumannii is the only species for which NAI-107 showed occa-
sionally a measured MIC. In this respect, it has been reported that
A. baumannii is generally more permeable to large antibiotics such
as novobiocin and erythromycin, possibly connected with the abil-
ity of Acinetobacter spp. to use long-chain fatty acids as growth
substrates.35
A growing body of evidence indicates the importance of killing
persisters and non-dividing cells in an infection setting.36 Overall,
the results of the current work, along with previously published re-
sults on the efficacy of NAI-107 in experimental models of infec-
tion,12,13 indicate that this lantibiotic represents a promising option
in addressing the serious threat of antibiotic resistance in Gram-
positive pathogens, with rapid killing of actively dividing and non-
dividing MRSA and GISA cells. In addition, the activity of NAI-107
against N. gonorrhoeae, its ability to kill non-dividing A. baumannii
and its strong synergism with polymyxin might provide additional
therapeutic options for treating infections by A. baumannii, E. coli,
K. pneumoniae and P. aeruginosa. From the limited comparisons
reported here, it appears that NAI-108 shares the same properties
as NAI-107.
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